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Abstract
The acronym Limprint stands for Lymphedema IMpact and PRevalence INTernational and was run under the
auspices of the International Lymphedema Framework (ILF), a charity dedicated to improving provision of care
globally. The primary aim was to identify the number of people with chronic edema (chronic edema present for >3
months and due to a range of underlying etiologies and associated risk factors) within diverse health services in nine
participating countries and to determine its impact using validated methods. An international protocol and sampling
framework, online data capture system, and standard operating procedures were adopted. An international consensus
was used to create a core data tool that covered 13 domains. Specialist data on demographics and disability, details of
swelling, wounds, cancer, and health-related quality of life were also available for sites. The study protocol was
designed to allow flexibility in the types of studies undertaken within complex health care systems. All cases were
confirmed using the modified pitting test. Sensitivity and specificity for this method were determined in Japanese and
European populations. Following confirmation of a chronic edema case, Lymphologists defined whether it was a
primary of a secondary form. The study was designed to provide robust evidence that chronic edema is an important
and unrecognized public health problem in health services with significant morbidity. Without evidence of the size
and complexity, it will remain considered a rare phenomenon and people affected will be denied access to appro-
priate treatment that would allow them to have fulfilled and productive lives.
Keywords: LIMPRINT, epidemiology, chronic edema, primary lymphedema, lymphoedema, secondary
lymphedema
Background
International Lymphedema Framework and National
Lymphedema Frameworks
Chronic edema remains a worldwide issue. TheLIMPRINTª study is at the core of the guiding prin-
ciples of the International Lymphedema Framework (ILF).1
The ILF is a U.K.-based charity whose aim is to improve the
management of chronic edema and related disorders world-
wide through research and the sharing of expertise and re-
sources. The ILF comprises member countries that subscribe
to the ideals of the ILF and have each developed their own
independent National Lymphedema Framework (NLF)—a
partnership of stakeholders (including: clinicians, academ-
ics, patients, lymphology organizations and other relevant
groups) dedicated to improving chronic edema care. An im-
portant part of the ILF strategy is to support countries in
acquiring and presenting data that will:
 Establish the size of the problem of chronic edema
 Provide the basis for evidence-based practice
 Be used to facilitate improved reimbursement
Rationale
This article describes the methods adopted in the devel-
opment and validation of the LIMPRINT study.
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LIMPRINT
The acronym LIMPRINT stands for Lymphedema IMpact
and PRevalence- INTernational Lymphedema Framework
and presents the aim of the study, which is ‘‘To determine the
impact and prevalence of chronic edema within health ser-
vices at a national and international level using a common
methodology.’’
LIMPRINT project overview
LIMPRINTª was a two-phased project. Phase 1 was
conducted between June 2013 and June 2014 with the de-
velopment and validation of the methods within two large
pilot projects. Phase II involved roll out across all sites
(9 countries and 40 sites) from June 2014 until August 2017.
Table 1 indicates the stages of the project plan.
Detailed Project Development
The stages of the LIMPRINT study are described below.
While presented as sequential stages, many of them ran
concurrently over the development phase.
Phase 1. Stage 1. Agreement
of the research methodologies
The approach taken for the LIMPRINT study was decided
during an international ILF conference in Montpellier in
2012.2 Key stakeholders from frameworks and methodologists
discussed the strengths and limitations of different epidemio-
logical approaches within complex and varied health care
systems. While it was acknowledged that large population-
based studies were the gold standard, this was not a realistic
option for the following reasons:
 Lack of international resources
B Census or reliable general population data from which
to draw random samples.
B Insurance data for random sampling in public health
care systems
 Large populations would require screening to generate
a modest sample size
 International coding systems do not exist to interrogate
existing data sets
 Bias in population and health service data sets
The core working group defined the key priority as ‘‘The
need to uncover the hidden burden of chronic edema on
health services.’’ A method of case ascertainment previously
used in the United Kingdom was adopted as the most flexible
approach using the following public health definition of
chronic edema.3,4:
‘‘Chronic edema is a broad term used to describe
edema, which has been present for more than three
months and involves one or more of the following ar-
eas: limbs, hands/feet, upper body (breast/chest wall,
shoulder, back), lower body (buttocks, abdomen),
genital (scrotum, penis, vulva), head, neck, or face.’’3
Primary aim and secondary objectives
The primary aim of LIMPRINT was ‘‘To determine the
number of people within health services suffering from
chronic edema and its impact upon them.’’ Many of these
people would not have been previously identified or be re-
ceiving treatment before screening during the study.
Table 1. Project Plan
Phase 1: Development and validation
Stages
1. Agreement of the research methodologies that could be
developed for international use in complex health care
systems
2. Literature review of prevalence study methods and
epidemiology
3. Development of questionnaires for the core and module
specialist tools
4. Development and validation of a classification for
chronic edema
5. Interrater reliability studies (pitting test and
classification of chronic edema in different
populations)
6. Construction and testing of the online database
7. Development of an international protocol and sampling
frameworks
8. Development of a support manual and educational
tools
9. Establishment of quality control mechanisms
Phase 2: Main study
Stages
1. Epidemiology studies undertaken in all participating
sites
2. Data quality monitoring
3. Data analysis and reporting
Table 2. Primary and Secondary Aims
of LIMPRINT
Primary aim
To determine the prevalence and functional impact of
chronic edema within health services at a national and
international level using modular epidemiological tools.
Secondary objectives
 To identify, using a case ascertainment questionnaire
(CORE TOOL), all patients within defined health
services within participating countries, who currently
suffer from chronic edema of longer than 3 months
duration.
 To determine the impact of chronic edema on the lives
of patients using questionnaires as follows:
B Demographic and disability assessment
B Health-related quality of life
B Details of swelling
B Wound assessment
B Cancer assessment
 To estimate the proportion of patients with chronic
edema who also have a wound in the same anatomical
area
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Secondary objectives were defined to fulfill the scope of
the project and were used to determine the study methods and
the modular data collection tools (Table 2).
The project aimed to facilitate the following types of
studies within each country:
 Facility-based prevalence studies: for example, a gen-
eral hospital or nursing home
 Geographically based prevalence: patients identified in
all health services within a defined area
 Specific patient populations: for example, specialist
lymphedema services, wound care clinics
 In-depth evaluation of a random sample of patients
(within facility- and geographically based studies) for
example, to classify type of chronic edema
Study infrastructure support and patient involvement
An international steering group of relevant experts, in-
cluding lymphologists, epidemiologists, and statisticians met
quarterly throughout the project to ensure project delivery.
A separate data monitoring committee was available to an-
swer any questions relating to data issues.
Individual patients and patient organizations within the
national frameworks were involved in all aspects of the study,
which conformed to current guidance for patient and carer
participation (INVOLVE guidelines).5
All countries and sites used the international study proto-
col and conducted the research in accordance with their
current ethical and research governance regulatory frame-
works and the International Declaration of Helsinki.6 All
sites complied with standard operating procedures on con-
ducting the study and quality control mechanisms.
Patient inclusion and exclusion criteria
The study patient inclusion and exclusion criteria are de-
fined in Table 3.
Methods
To comply with the overall study, the presence and chro-
nicity of edema was confirmed by two methods before
chronic edema was judged to be present. This screening test
was undertaken at each participating site by staff trained in
the data collection methods. In specialist lymphedema ser-
vices, all patients had been assessed by lymphologists before
data collection and the classification of the chronic edema
defined. Further description of the methods required in dif-
ferent health care settings is defined below.
Confirmation of chronic edema was based on the following
two factors:
 First, the existence of edema was determined based on
an observational ‘‘Pitting Edema Test,’’ which is
widely used in clinical practice and been shown to be
valid and reliable.7 The pitting test was carried out by
pressing the thumb into the site of the swelling for 10
seconds. If a pit remained upon removal of pressure,
then pitting edema was judged to be present. The
presence of edema was tested in all body parts, using a
standard protocol, including the upper and lower limbs,
trunk, face, and neck.
 Second, edema was judged to be chronic if it had been
present for 3 months or more. This factor was determined
on the basis of feedback received from the patient, or if
this was not possible, from carers and clinicians who
have known the person for at least 3 months.
 In community nursing home studies in the United
Kingdom, additional questions were included to ensure
that the clarification of chronic edema was correct.
Phase 1. Stage 2. Literature review of prevalence
study methods
A literature review of the current evidence had been un-
dertaken under the leadership of the American Lymphedema
Framework Project (ALFP).8 This confirmed the lack of
evidence available and informed the design of the study and
the methods used for data collection.
Phase 1. Stage 3. Development of the core
and module data collection methods
The study design included a core tool, which was com-
pleted on all patients irrespective of the type of study. Ad-
ditional tools were developed for use in more complex
projects. The outline of the tools, the methods of use, and the
data they provide are outlined in Table 4.
Development of the core tool
The development of the core tool followed a consultative
approach with an International expert panel and eight par-
ticipating NLFs. The resulting core tool had 13 domains
(Table 5). The initial questions were generated within an
international conference (4th International Lymphedema
Framework Conference, June 2012, Montpellier, France) and
the questions ranked in order of importance. The tool initially
included 21 domains but this was reduced to 13 following the
consultation process.
The questions covered the most essential information re-
quired to understand the prevalence of chronic edema and its
impact on health services. The tool was simple and rapid to
complete. Translation and back translation of the core wound
and swelling tools have been undertaken in Danish, French,
Turkish, Italian, and Japanese thus adding another level of
validation.
Table 3. Inclusion and Exclusion Criteria
Inclusion criteria
All ages (data on children only available from specialist
services).
Has chronic edema of longer than 3 months.
Is able to understand the study as set out in the
information sheet.
Is able to give informed consent, that is, (gives explicit
consent for their data to be transferred into an
international data base).
Exclusion criteria
Is unwilling or unable to participate for whatever reason.
Is receiving end-of-life care.
When considered to not be in the patient’s best interest
(decided by the lead clinician managing their care).
LIMPRINT—METHODS AND VALIDATION 129
Data fields within the core tool
The core tool identified key information about access to care
and the types of treatment. This included whether any treat-
ment was being given or not. For those receiving treatment,
data were collected on the elements of complex decongestive
therapy: skin care, exercise, manual lymphatic drainage, and
types of compression. Other treatments noted included anti-
biotics, psychological support, and surgical treatments such as
liposuction.
A body map was used to record the sites of swelling and the
presence and nature of any concurrent wounds. Lower and
upper mobility status was defined using a previously pub-
lished classification.9 Information about the history of cel-
lulitis and its treatment was recorded, including use of
antibiotics and episodes requiring hospitalization. A WHO
general category of weight was adopted due to the lack of
available BMI for many, particularly those seen in commu-
nity settings.10 Important comorbidities linked to chronic
edema were also recorded.
The teams screening the patient were asked to make a
subjective judgment about whether the swelling was con-
trolled or not. While it is recognized that this question is open
to professional interpretation, nevertheless this is an impor-
tant issue that has previously been linked to whether patients
are accessing treatment.3
Further questions examined whether chronic edema was a
factor in determining or delaying discharge from hospital or
was a reason for long-term community care. Issues of access
Table 4. Tools, Methods, and Data Delivered
Tool Method Deliverables
Core tool
Questionnaire completed
by health care professionals
Profile of patients with
chronic edema
Core case ascertainment questionnaire.
Chronic edema confirmed
by pitting test and confirmation
of history of chronic
edema >3 months
Age/gender/duration
and site of chronic edema
Identification of patients with chronic
edema in health care systems
Subjective control of swelling
Used in all studies
Level of obesity
Mobility
Relevant comorbidities
Classification of cause
of chronic edema
Previous treatment
Cellulitis history
Presence of a wound
Access to treatment
Module tools
Data were gathered from patients using
clinical assessment and interviews,
either by self-completion or
completion by a health professional.
The Module Tools collected
data that looked in more
depth at factors affecting
the life of the patient
as well as care delivery,
such as the impact on
discharge from hospital
or accessing appropriate care,
including:
Assessment of functional impact.
Personal details, including
living status, educational
attainment, employment status
Demographics and Disability
assessment (WHODAS 2.0)
Details of swelling
Quality-of-life assessment
(LYMQOL+EQ-5D+ LFSQQ)
Mobility status
Details of swelling
Quality of life
Wound assessment
Impact of cancer
Cancer details
Type and impact of wound
Factors affecting delivery
of care and discharge
Resource use
Table 5. The domains of the Core Tool
1. Type of facility in which
data are collected
2. Demographics
3. Level of obesity 4. Mobility
5. Relevant comorbidities 6. Classification
of lymphedema
7. Lymphedema history 8. Cellulitis History
9. Categories of treatment 10. Site of swelling
11. Wound area 12. Access to treatment
13. Subjective control
of swelling
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to specialist treatment and the distance from services were
also recorded.
Expert review of the core tool
Each of the 8 participating frameworks engaged 10 pro-
fessionals (generalists and specialists) to review the core tool
using a set of 5 validated case studies to complete the tool and
decide the classification. Data were entered into the database
and the results were compared by five independent lym-
phologists for accuracy of classification and data quality. Of
the 400 complete case reviews, correct classification oc-
curred in 387/400 (97%). The 13 cases in which classification
differed related to the decision about whether the case was
due to primary or secondary lymphedema. This is a well-
known and valid difficulty for clinicians.
Module tools
The Module Tools aimed to assess the functional and
quality-of-life impact using validated tools where possible.
Further clinical information about wounds and treatment
(where present) and details of the severity of swelling were
included. Module Tools covered the following areas:
Demographics and disability (WHODAS 2.0)
This well-validated tool included questions that explored
the patient’s personal circumstances for example, housing,
employment, and education. WHODAS 2.0 is a 12-item
disability assessment schedule completed by the patient.11
Quality of life (LYMQOL and EQ-5D and LFSQQ)
Quality of life was assessed with a combination of disease-
specific and generic tools.
 LYMQOL is a validated condition-specific quality-of-life
assessment instrument (it is not specifically validated
for patients with lymphatic filariasis) that assesses the
impact of lymphedema on the patient’s everyday living
and health-related quality of life. The tool is validated
for lower and upper limbs.12
 EQ-5D is a generic quality-of-life instrument applica-
ble to a wide range of health conditions and provides a
simple descriptive profile and single index value for
health status.13
 LFSQQ (Lymphatic Filariasis-Specific Quality-of-Life
Questionnaire) is a condition-specific instrument for pa-
tients with lymphatic filariasis. The LFSQQ is intended
for use for patients within filarial areas and the ques-
tionnaire was developed based on an Indian lifestyle.14
Details of swelling
This tool provided further details about the swelling. Each
study site elected one measurement technique, which was
standardized for all patients.
Limb circumference and volume measures
Standardized circumferential limb measurements using a
tape measure were the most widely used and accessible tech-
nique. Upper and lower limb circumference were measured
bilaterally at two points according to the site of swelling:
B mid-upper arm (10 cm proximal to the olecranon
process)
B forearm (10 cm distal to the olecranon process)
B mid-thigh (20 cm proximal to the patella)
B calf (20 cm distal to the patella)
Limb volume methods (specialist centers)
Limb volume measures were undertaken in centers with
access to specialist methods. Limb volume was expressed in
milliliters for each limb using a standard method for all pa-
tients within the study site. The methods included water
displacement and Perometry.
Kaposi–Stemmer sign
The Kaposi–Stemmer sign involved pinching a skin fold at
the base of the second toe or middle finger of the limb that had
edema.15 The sign was judged to be positive if the skin could
not be lifted and negative if the skin could be lifted normally.
Collectively, these data were used to describe and classify
severity using the International Society of Lymphology
staging tool16–18:
 ISL stage I: Early onset of the condition, where there is
accumulation of tissue edema that subsides with limb
elevation. The edema may be pitting at this stage.
 ISL stage II: Limb elevation alone rarely reduces
swelling and pitting is manifested.
 ISL stage III: The tissue is hard (fibrotic) and pitting is
absent. Skin changes such as thickening, hyperpig-
mentation, increased skin folds, fat deposits, and warty
overgrowths develop.
Wounds
This tool provided data about all wounds, including type of
wound, location, severity, wound area, wound duration,
history of infection, and frequency of dressing changes.
 Cancer
A specific tool for patients whose chronic edema was the
consequence of cancer treatment or a direct effect of the
disease was developed. This was a 14-domain questionnaire
focusing on types of cancer and surgical and nonsurgical
treatments. The types of cancer included were:
Breast Cervical
Endometrial Ovarian
Bladder Vulval
Colorectal Melanoma
Head and neck Other cancers
Table 6. Classification of Chronic Edema
Primary Lymphedema
Secondary Lymphedema Cancer
Noncancer
Contributory factors:
venous disease,
obesity, immobility,
other (free text)
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Phase 1. Stage 4. Development and validation
of a classification for chronic edema
A 15-member expert panel reviewed and assessed a set of
eight case studies for content and face validity and to ensure
that they reflected the chronic edema classification categories
contained in the core tool. There was a 100% response rate.
Five of the eight case studies achieved a 90% agreement level
for the classification of lymphedema and these five case
studies were used for the review of the core tool in stage 4.
The classification was made on whether the chronic edema
was of primary origin or due to secondary causes (Table 6). In
those with a secondary cause a number of key suspected
contributory factors were included, such as venous disease
and obesity. During the studies specialist lymphology teams
undertook this classification where patients had been identi-
fied and confirmed to have chronic edema.
Stage 5. Interrater reliability studies
The LIMPRINT study included a number of interrater
reliability studies to assess the accuracy of detection of
chronic edema using the pitting test and the other methods of
clarification.
Dai et al.7 undertook a cross-sectional study within a long-
term care hospital in Japan. The interrater reliability of the
pitting test for evaluating edema was tested for 34 locations
of the body. The pitting test was applied for 10 seconds with a
similar force to that used by the expert assessor who acted as a
‘‘gold standard.’’ Detection of the presence of edema on re-
moval of pressure was assessed using the modified Fukazawa
method19 described in Table 7.
Five bedridden patients were assessed by the gold refer-
ence and four independent assessors. Agreement among the
assessors was high at >0.85 with the kappa coefficient
showing fair agreement (range 0.51–0.81) (Table 8).
The same methodology was used in three U.K. studies.
Two of the studies involved patients seen by community
nursing services and one with patients within a residential
care facility. Results from these studies confirmed a high rate
of detection of chronic edema although mild edema was
missed by a proportion of community nurses compared with
the expert assessor.
Phase 1. Stage 6. Construction and testing
of the online database
Security and international requirements of the online
data base. LIMPRINT data were managed by an electronic
data management system that had a comprehensive set of
security features that included the storage of data in en-
crypted form and individualized password-controlled access.
The system had an audit trail, which tracked all activity on
the system, including changes to data. As an added security
feature, the user was automatically logged out after 10
minutes of inactivity, requiring a password to restart the
application. An edit check function in the form of a Data
Clarification Form was developed to check for flagging,
missing, invalid, incomplete, or questionable data and re-
quired study-site clarification before the data were marked
as complete. Individual sites had access to only their own
data. The project manager and statisticians were able to
access all data from the sites.
During the project, the data system was evaluated by the
participating frameworks to ensure that it was fit for purpose
and to access the training requirements for each site. Central
training for all users was undertaken by ILF project manager
and data management team.
Data transfer and compliance. The study faced impor-
tant considerations relating to data protection and transfer of
data. For countries within the European Union (EU), the EU
Data Protection Directive guides such legislation places are
restrictions on the exporting of confidential data to countries
outside the EU. This includes the United States where the
database was located. Within these restrictions the transfer
of data was permitted provided three criteria were met:
 There was confirmation that the system complied with
all EU Data Protection legislations and could ensure
that sensitive health data were protected.
 The data were anonymized.
 Patients gave explicit consent to the transfer of their
data to a country outside the EU.
In sites where transfer of data outside of Europe was
prohibited due to research governance issues, the data were
entered on to a password-protected data collection system
using the same data capture fields and stored on secure
servers.
Table 8. Interrater Reliability
Results from Japan
Rater ID
Agreement rate
with ‘‘gold standard’’
Cohen’s kappa
coefficient
1 0.88 0.51
2 0.90 0.60
3 0.94 0.81
4 0.88 0.51
Table 7. Modified Fukazawa Method
of Assessment for Detection of Pitting Edema
Grade Criteria
0 There is no impression (no edema present)
1 Impression of the outline of the dimple is
slightly differentiated by release of
pressure and sometimes appears
to be absent
2 Impression does not become clear at the
beginning of pressure but occurs with
further pressure and an impression
is left after release
3 Deep impression remains after release
of pressure that is clear on visual
inspection at initiation of pressure
Nonpitting
Edema
(added
to method)
Indentation made by pressure does
not persist (nonpitting edema as seen
in patients with hard tissue)
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Phase 1. Stage 7. Development of an international
protocol and sampling frameworks
The international protocol included a detailed description
of the sampling procedures and study methods and was used
in all sites.
Methods for sampling in geographically based
prevalence study
A comprehensive list was collated for each geographical
area of all acute hospitals and relevant community health
services that may meet people who have chronic edema.
Examples of such services included:
B General medical practitioner.
B Specialist community medical practitioner.
B Community nursing/home care nursing service.
B Nursing home.
B Elderly care residential home.
B Specialist lymphedema service.
B Acute hospital services (in-patient or/and outpatient).
A sampling frame was created, with the aim of the re-
cruitment strategy to ensure that the widest range of patients
were identified with different underlying conditions and
comorbidities.
Hospital prevalence studies
In hospital settings, a sampling framework of all wards and
departments in which patients with chronic edema would be
found was developed. The screening was undertaken in a
single day or over several days in larger facilities. Trained
staff screened all patients who consented to participate irre-
spective of their underlying disease or treatment regimen.
Teams of researchers undertook the study with a lympholo-
gist assigned to each team to undertake the chronic edema
classification.
The bed capacity of each ward or unit was recorded, plus
the number of beds occupied, the number of patients re-
cruited, and the number excluded from consideration and the
reasons for this. This enabled the prevalence to be calculated
accurately in hospital settings.
Community-based prevalence studies
All staff in relevant community health services were asked
to approach each person on their existing case list to provide
information and gain consent. All generalist practitioners
participating in the study received training in the completion
of the tools. The collection of data took place prospectively
over a time frame, generally of 4 weeks and required all
patients to be clinically screened and assessed. Numbers on
community caseloads were recorded and those excluded from
the study. The method of classification of chronic edema
varied in different settings but included the use of specialist
lymphedema therapist and tissue viability teams in some
settings. In areas where this support was not available the
more detailed classification was omitted (three studies in the
United Kingdom).
Random sampling techniques
A random sample was used in some population or facility-
based studies, where a large number of patients with chronic
edema was identified but additional modular tools were re-
quired. A random permuted block design allowed for a one
third sample to be taken. Following completion of the core
tool, the investigator checked the patient numbers of those
identified with chronic edema against a pregenerated ran-
domized list of sequential patient numbers to decide whether
the patient was to be interviewed. Each clinical team held an
individual randomization list.
Specialist service profiles
LIMPRINT provided a unique opportunity to understand
the profile of patients seen within specialist lymphedema and
other types of services in different countries and to compare
this with patients found in other settings. Patients gave in-
formed consent for their inclusion in study sites, where ethics
approval required this. The accuracy of the service lists was
checked to ensure that it was up to date and discharge and
deaths had been removed. Information on their edema status
was based on their last visit and the type of lymphedema was
taken from the clinical case records. As these patients were in
specialist lymphedema services, the underlying stratification
of primary and secondary lymphedema was already deter-
mined in addition to the comorbidities required for comple-
tion of the core tool.
Phase 1. Stage 8. Development of a support manual
and educational tools
LIMPRINT required the development of a range of edu-
cational materials to ensure that the data were collected ac-
curately. This included a manual to supplement the protocol.
Formal training standards were written that included a
checklist of training and competency for all those collecting
data. A video using reuseable learning outcomes was made to
demonstrate how to undertake the pitting test, recognition of
a positive stemmer sign, and fibrosis. All facility-based
studies commenced with a half day training program that
included checking of the first assessment by specialist prac-
titioners. Data quality was enhanced by teams of researchers
working in clinical areas, where any complex clinical ques-
tions could be confirmed before leaving the area.
Phase 1. Stage 9. Establishment of quality
control mechanisms
A range of quality control mechanisms was established.
Preventing double counting
The prevention of double counting was essential to achieve
an accurate prevalence. The double counting of patients was
likely to take place within a geographical area when a patient
might be identified by more than one service delivering care
to the same patient or in an acute care setting if a patient
moved departments. This was prevented by the allocation of a
nonidentifiable number that was matched with a master
identifier list of patients.
Data quality checks
In addition to the quality checks within the electronic data
system, additional checks were made of the paper-based data
collection tools. Within each facility, quality monitors were
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established to check completeness of data from each clinical
area before the research teams left the area and all forms were
checked by a central coordinator. Similar mechanisms were
established for community studies.
Conclusion
The standardization of methods used in the LIMPRINT
study provided a framework that allowed sites in different
countries and from different facilities and types of health care
systems to work together. The completion of LIMPRINT also
demonstrated that an international initiative, which was
supported by a strong ethos of partnership, could be under-
taken. The results from the different studies will be discussed
in a portfolio of articles.
The LIMPRINT team would like to thank all the sites for
their contribution in generating the data for this study and
their commitment to the ILF.
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